Replies to post #179084 on Biotech Values

[biomaven0]

>>meets primary endpoint in phase-3b migraine study

Well oral sumatriptan is fairly slow-acting, so they were pretty much going up against a placebo in their 30 minute endpoint.

The standard FDA endpoint is pain relief at 2 hours. They didn't disclose those numbers, although likely they would have been OK.

Oral sumatriptan is clearly (but not dramatically) inferior to the 2nd-generation triptans in effectiveness and side-effect profile. A good example of how sometimes first-in-class in this type of indication keeps a good market share although inferior to best-in-class.

Peter

[acgood]

AVNR - sometimes you'd never guess which companies will (might) end up with THREE successful NDAs when so many can't even come close to one

[dugafish]

re: AVNR migraine-I understand that AVNR's migraine drug improves absorption and provides faster relief with less drug...I just wonder about adoption...if many patients are really going to use this breath powered device instead of a simple pill?